Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoldonrasib + TNG462
- Development stage
- Unknown
- Lead developer
- Tango Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination of **zoldonrasib** (RMC-9805), a selective small molecule inhibitor targeting KRAS G12D (a RAS(ON) inhibitor) developed by Revolution Medicines, and **TNG462** (also known as vopimetostat), a synthetic lethal, oral, MTA-cooperative PRMT5 inhibitor developed by Tango Therapeutics. This combination is in clinical trials in patients with MTAP-deleted and RAS mutant metastatic pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC). The dual inhibition approach targets both oncogenic KRAS G12D signaling (by zoldonrasib) and drives synthetic lethality in MTAP-deficient cells (by TNG462), aiming to maximize anti-tumor efficacy in genetically selected populations.
- Other names
- zoldonrasib + TNG462RMC-9805 + TNG462zoldonrasib + vopimetostat
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on zoldonrasib + TNG462.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoldonrasib + TNG462.